½ÃÀ庸°í¼­
»óǰÄÚµå
1800893

Àü±â»ý¸®ÇÐ ±â±â ½ÃÀå º¸°í¼­ : Á¦Ç°, ÀûÀÀÁõ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2025-2033³â)

Electrophysiology Devices Market Report by Product, Indication (Atrial Fibrillation, Supraventricular Tachycardia, Atrioventricular Nodal Re-entry Tachycardia, Wolff-Parkinson-White Syndrome, Bradycardia, and Other), End User, and Region 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 148 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è Àü±â»ý¸®ÇÐ ±â±â ½ÃÀå ±Ô¸ð´Â 2024³â 67¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. IMARC GroupÀº 2033³â±îÁö ½ÃÀå ±Ô¸ð°¡ 129¾ï ´Þ·¯¿¡ ´ÞÇϰí, 2025-2033³â 7.58%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ºÎÁ¤¸Æ »ç·Ê Áõ°¡, ±â¼ú ¹ßÀü, Àúħ½ÀÀû ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀÇ·áºñ Áõ°¡, ¿Ü·¡ Ä¡·á ȯ°æ È®´ë, À¯¸®ÇÑ »óȯ Á¤Ã¥, Á¶±â Áø´Ü¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ÀÇ·á±â±â¿¡ ÀΰøÁö´É(AI) ÅëÇÕ µîÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

Àü±â»ý¸®ÇÐ ±â±â ½ÃÀå µ¿Çâ :

½ÉÀå ºÎÁ¤¸ÆÀÇ À¯º´·ü Áõ°¡

½É¹æ¼¼µ¿(AF) ¹× ±âŸ ´Ù¾çÇÑ ¾Ç¼º Áúȯ°ú °°Àº ½ÉÀå ºÎÁ¤¸ÆÀÇ À¯º´·ü Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¾÷°è º¸°í¼­¿¡ µû¸£¸é, ½É¹æ¼¼µ¿(AF)Àº ½ÉÀåÀÇ Àü±âÀû ¶Ç´Â ½ÅÈ£/Ç÷¯ÅÍ ¹®Á¦·Î ¾Ë·ÁÁ® ÀÖÀ¸¸ç, ¹Ì±¹¿¡¼­ ¾à 270¸¸ ¸íÀÌ ¾Î°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ½É¹æ¼¼µ¿Àº ³úÁ¹Áß°ú ½ÉºÎÀüÀÇ °¡Àå ÈçÇÑ ¿øÀÎÀ¸·Î ÀÇ·á¼­ºñ½º¿¡ ´ëÇÑ ºÎ´ãÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±â¼úÀÇ ¹ßÀü°ú °¡Ã³ºÐ ¼Òµæ Áõ°¡·Î ºÎÁ¤¸Æ¿¡ ´ëÇÑ È¯ÀÚµéÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Á¶±â Áø´Ü ¹× Á¶±â Ä¡·á°¡ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù.

Àü±â »ý¸®ÇÐ ÀåÄ¡ÀÇ ±â¼ú ¹ßÀü

Àü±â »ý¸®ÇÐ ÀåÄ¡ ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î ±Þ¼ÓÇÑ ±â¼ú ¹ßÀü¿¡ ÀÇÇØ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. 3D ¸ÅÇÎ ½Ã½ºÅÛ ¹× ±âŸ ±â¼ú Çõ½ÅÀ» ÅëÇØ ½ÉÀå Àü¹®ÀÇ´Â ½ÉÀåÀÇ Àü±âÀû Ȱµ¿ÀÇ Æ¯Á¤ ¸ðµ¨À» ¼³°èÇÒ ¼ö ÀÖ°Ô µÇ¾î ºÎÁ¤¸Æ ȯÀÚÀÇ Áø´Ü°ú Ä¡·á¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ä«Å×ÅÍ ÀýÁ¦¼ú ±â¼úÀÇ ¹ßÀüÀº ½Ã¼úÀÇ À§ÇèÀ» ÁÙÀ̰í, ȯÀÚÀÇ È¸º¹ ½Ã°£À» ÃÖ¼ÒÈ­Çϸç, ¼º°ø·üÀ» ³ôÀÌ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Àü±â »ý¸®Çп¡¼­ ·Îº¿ º¸Á¶ ½Ã½ºÅÛÀÇ »ç¿ëÀº ¼ö¼ú Áß Á¤È®µµ¿Í Á¦¾î¸¦ Çâ»ó½ÃÄÑ ½ÃÀå ¼ºÀåÀ» Å©°Ô ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Àúħ½ÀÀû ½Ã¼úÀÇ ¼ºÀå

ÃÖ¼Òħ½À(MI) Àü±â»ý¸®ÇÐÀû ½Ã¼úÀº ȸº¹ ½Ã°£, ÀÔ¿ø ±â°£, ½Ã¼ú À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ¾î ȯÀÚ Ä¡·á¿¡ Å« ¼ö¿ä¸¦ ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ºÎÁ¤¸Æ Ä¡·á¿¡ »ç¿ëµÇ´Â Ä«Å×ÅÍ ÀýÁ¦¼ú°ú °°Àº ½Ã¼úÀº Ç¥ÁØ ¼ö¼úÀÇ ´ë¾ÈÀ¸·Î º¸´Ù ´ú ¿Ü»óÀûÀÎ ´ë¾ÈÀ» Á¦°øÇÕ´Ï´Ù. À̸¦ ÅëÇØ ´õ¿í Á¤È®ÇÑ Áø´ÜÀÌ °¡´ÉÇØÁ® ȯÀÚÀÇ ¼ö¼ú ºñ¿ë°ú ºÎ´ãÀ» ÁÙÀ̸鼭 Ä¡·á °á°ú¸¦ ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, À̹Ì¡ ¹× ¸ÅÇÎ ±â¼úÀÇ °³¹ßÀº MI °³ÀÔÀ» ´õ ¹ø°Å·Ó°Ô ¸¸µéÁö ¾Ê°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • º¸ÅÒ¾÷ Á¢±Ù
    • Åé´Ù¿î Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

Á¦5Àå ¼¼°èÀÇ Àü±â»ý¸®ÇÐ ±â±â ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • Ä¡·á ±â±â
    • ÁÖ¿ä À¯Çü
      • »ðÀÔÇü Á¦¼¼µ¿±â(ICD)
      • ÀÚµ¿ ü¿Ü½Ä Á¦¼¼µ¿±â(AED)
      • ÆäÀ̽º¸ÞÀÌÄ¿
      • CRT-P
      • CRT-D
      • Ä«Å×ÅÍ
      • ±âŸ
  • Áø´Ü Àåºñ
    • ÁÖ¿ä À¯Çü
      • ȦÅÍ ½ÉÀüµµ ¸ð´ÏÅ͸µ ±â±â
      • Áø´Ü¿ë Àü±â»ý¸®ÇÐ Ä«Å×ÅÍ
      • ½ÉÀüµµ(ECG)
      • EP ¸ÅÇÎ ¹× À̹Ì¡ ½Ã½ºÅÛ
      • »ðÀÔÇü ½ÉÀå ¸ð´ÏÅÍ(ICM)
      • ±âŸ

Á¦7Àå ½ÃÀå ºÐ¼® : ÀûÀÀÁõº°

  • ½É¹æ¼¼µ¿(AF)
  • »ó½Ç¼º ºó¹Ú
  • ¹æ½Ç°áÀý ÀçÁøÀÔ¼º ºó¸Æ(AVNRT)
  • ¿ïÇÁ ÆÄŲ½¼ È­ÀÌÆ® ÁõÈıº(WPW)
  • ¼­¸Æ
  • ±âŸ

Á¦8Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • Áø´Ü¼¾ÅÍ
  • ±âŸ

Á¦9Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå SWOT ºÐ¼®

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå PorterÀÇ Five Forces ºÐ¼®

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Biosense Webster Inc.(Johnson & Johnson)
    • Biotronik SE & Co. KG
    • Boston Scientific Corporation
    • Cardiofocus Inc.
    • Koninklijke Philips N.V.
    • Medtronic Inc.
    • MicroPort Scientific Corporation
    • Molecular Devices LLC(Danaher Corporation)
    • Nihon Kohden Corporation
    • Siemens Healthcare GmbH
    • Stereotaxis Inc.
LSH 25.09.05

The global electrophysiology devices market size reached USD 6.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 12.9 Billion by 2033, exhibiting a growth rate (CAGR) of 7.58% during 2025-2033. Rising cardiac arrhythmia cases, technological advancements, growing demand for minimally invasive procedures, increasing healthcare expenditure, expanding outpatient care settings, favorable reimbursement policies, escalating awareness of early diagnosis, and the integration of artificial intelligence (AI) in medical devices are some of the factors driving the market growth.

Electrophysiology Devices Market Trends:

Rising Prevalence of Cardiac Arrhythmias

Increasing prevalence of cardiac arrhythmias such as atrial fibrillation (AF) and various other malignant are driving the market growth. According to the industry reports, atrial fibrillation (AF), known as the electrical or signaling/flutter problem in the heart, is affecting almost 2.7 million people in United States. AF is the most common cause of strokes and heart failure, which is creating a growing burden on health services. In addition, expanding technological advancements and disposable income has boosted awareness about arrhythmias among patients, due to which they prefer early diagnosis and treatment.

Technological Advancements in Electrophysiology Devices

The growth of the electrophysiology devices market is primarily bolstered by the rapid technological advancements. 3D mapping systems and other innovations enable cardiologists to design specified models of the heart's electrical activity, which improves diagnosis and treatment for patients suffering with arrhythmias. Additionally, the improvements in catheter ablation technologies helps reduce procedural risks, while minimizing patient recovery times and increasing success rates. In line with this, the use of robotic-assisted systems in electrophysiology has also improved the precision and control during procedures, which is providing a considerable boost to the market growth.

Growth of Minimally Invasive Procedures

Minimally invasive (MI) electrophysiology procedures can reduce recovery times, hospital stays, and procedural risks, which is why they are witnessing a considerable demand for the treatment of patients. Procedures such as catheter ablation, which are used to treat arrhythmias, provide a less traumatic alternative to the standard surgeries. This further enables an accurate diagnosis and enhances the results of treatment at a reduced cost and strain of surgeries on patients. Apart from this, the development of imaging and mapping technologies, in turn, has made MI interventions less cumbersome, which is facilitating the market growth.

Electrophysiology Devices Market Segmentation:

Breakup by Product:

  • Treatment Devices
    • Implantable Cardioverter Defibrillators (ICDs)
    • Automated External Defibrillators (AEDs)
    • Pacemakers
    • CRT-P
    • CRT-D
    • Catheters
    • Others
  • Diagnostic Devices
    • Holter Monitoring Devices
    • Diagnostic Electrophysiology Catheters
    • Electrocardiograph (ECG)
    • EP Mapping & Imaging Systems
    • Insertable Cardiac Monitors (ICM)
    • Others

Diagnostic devices accounts for the majority of the market share

The diagnostic devices segment is driven by the increasing prevalence of cardiovascular diseases, particularly arrhythmias, which require precise diagnosis for effective treatment. Technological advancements, such as improved electrocardiographs (ECGs) and EP mapping systems, are enhancing diagnostic accuracy, leading to wider adoption of these devices. Additionally, the growing awareness of early detection and prevention of heart conditions is boosting demand for diagnostic tools like Holter monitors and insertable cardiac monitors (ICMs). Healthcare providers are increasingly relying on these devices for continuous monitoring and accurate data collection, which improves patient outcomes. The rise in minimally invasive diagnostic procedures, which offer quicker recovery times and reduce the need for hospital stays, is further contributing to the segment's growth.

Breakup by Indication:

  • Atrial Fibrillation (AF)
  • Supraventricular Tachycardia
  • Atrioventricular Nodal Re-entry Tachycardia (AVNRT)
  • Wolff-Parkinson-White Syndrome (WPW)
  • Bradycardia
  • Other

Atrial fibrillation (AF) holds the largest share of the industry

The atrial fibrillation (AF) segment is driven by the increasing global prevalence of AF, particularly among aging populations, which is a leading cause of stroke and heart failure. As awareness about AF grows, there is a rising demand for early diagnosis and effective treatment, prompting healthcare providers to invest in advanced electrophysiology devices. Technological advancements in diagnostic tools, such as 3D mapping systems and catheter ablation technologies, have improved the accuracy of AF detection and treatment success rates, boosting adoption. Additionally, the growing preference for minimally invasive procedures, which offer faster recovery times and reduced complications, is further accelerating demand for electrophysiology devices in AF management.

Breakup by End User:

  • Hospitals
  • Diagnostic Centers
  • Others

Hospitals represents the leading market segment

The hospital segment is driven by the increasing prevalence of cardiovascular diseases, particularly arrhythmias, which require specialized electrophysiology procedures. Hospitals are equipped with advanced technology, such as 3D mapping and catheter ablation systems, enabling them to offer comprehensive cardiac care. The growing demand for minimally invasive procedures, which are often performed in hospital settings, further fuels this segment. Additionally, hospitals have skilled healthcare professionals capable of handling complex electrophysiology treatments, which boosts patient confidence in seeking care at these facilities. Rising healthcare expenditure, particularly in developed regions, allows hospitals to invest in cutting-edge electrophysiology devices, enhancing their capabilities.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest electrophysiology devices market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for electrophysiology devices.

As per the electrophysiology devices market dynamics, the North America's regional market is driven by the increasing prevalence of cardiovascular diseases, particularly atrial fibrillation, among the aging population. Advanced healthcare infrastructure and widespread access to cutting-edge medical technologies support the adoption of electrophysiology devices across the region. Rising awareness of early diagnosis and treatment of heart conditions is boosting demand for these devices. Additionally, the growing preference for minimally invasive procedures has increased the use of catheter ablation and other electrophysiology tools. Continuous advancements in medical technology, such as 3D mapping systems and artificial intelligence (AI) integration, enhance the accuracy and outcomes of procedures, making them more attractive to both patients and healthcare providers, which is further driving the electrophysiology devices demand.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the electrophysiology devices industry include Biosense Webster Inc. (Johnson & Johnson), Biotronik SE & Co. KG, Boston Scientific Corporation, Cardiofocus Inc., Koninklijke Philips N.V., Medtronic Inc., MicroPort Scientific Corporation, Molecular Devices LLC (Danaher Corporation), Nihon Kohden Corporation, Siemens Healthcare GmbH, Stereotaxis Inc., etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • Key players in the electrophysiology devices market are focusing on technological innovation and product development to stay competitive. They are investing in research and development (R&D) to create more advanced devices, such as next-generation catheter ablation systems and 3D mapping technologies, which offer improved precision and patient outcomes. Companies are also expanding their product portfolios by introducing new minimally invasive devices, making procedures less risky and more efficient. Strategic collaborations with hospitals and healthcare institutions are enabling key players to enhance their presence and strengthen their market share. In addition, many are adopting artificial intelligence and machine learning in their devices to enhance diagnostic capabilities and data interpretation, improving real-time decision-making during procedures.

Key Questions Answered in This Report

  • 1.What was the size of the global electrophysiology devices market in 2024?
  • 2.What is the expected growth rate of the global electrophysiology devices market during 2025-2033?
  • 3.What are the key factors driving the global electrophysiology devices market?
  • 4.What has been the impact of COVID-19 on the global electrophysiology devices market?
  • 5.What is the breakup of the global electrophysiology devices market based on the product?
  • 6.What is the breakup of the global electrophysiology devices market based on the indication?
  • 7.What is the breakup of the global electrophysiology devices market based on the end user?
  • 8.What are the key regions in the global electrophysiology devices market?
  • 9.Who are the key players/companies in the global electrophysiology devices market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Electrophysiology Devices Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Treatment Devices
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Implantable Cardioverter Defibrillators (ICDs)
      • 6.1.2.2 Automated External Defibrillators (AEDs)
      • 6.1.2.3 Pacemakers
      • 6.1.2.4 CRT-P
      • 6.1.2.5 CRT-D
      • 6.1.2.6 Catheters
      • 6.1.2.7 Others
    • 6.1.3 Market Forecast
  • 6.2 Diagnostic Devices
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Holter Monitoring Devices
      • 6.2.2.2 Diagnostic Electrophysiology Catheters
      • 6.2.2.3 Electrocardiograph (ECG)
      • 6.2.2.4 EP Mapping & Imaging Systems
      • 6.2.2.5 Insertable Cardiac Monitors (ICM)
      • 6.2.2.6 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Indication

  • 7.1 Atrial Fibrillation (AF)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Supraventricular Tachycardia
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Atrioventricular Nodal Re-entry Tachycardia (AVNRT)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Wolff-Parkinson-White Syndrome (WPW)
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Bradycardia
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Other
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostic Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Biosense Webster Inc. (Johnson & Johnson)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Biotronik SE & Co. KG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Boston Scientific Corporation
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Cardiofocus Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Koninklijke Philips N.V.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Medtronic Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 MicroPort Scientific Corporation
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Molecular Devices LLC (Danaher Corporation)
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Nihon Kohden Corporation
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Siemens Healthcare GmbH
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Stereotaxis Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦